"Tegafur" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
MeSH Number(s)
D03.383.742.698.875.404.850
Concept/Terms
Tegafur- Tegafur
- 1-(Tetrahydro-2-furanyl)-5-fluorouracil
- N1-(2'-Tetrahydrofuryl)-5-fluorouracil
- 1-(2-Tetrahydrofuryl)-5-fluorouracil
- 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione
Utefos- Utefos
- Prasfarma Brand of Tegafur
- Almirall Brand of Tegafur
Uftoral- Uftoral
- Bristol-Myers Squibb Brand of Tegafur
- Bristol Myers Squibb Brand of Tegafur
Below are MeSH descriptors whose meaning is more general than "Tegafur".
Below are MeSH descriptors whose meaning is more specific than "Tegafur".
This graph shows the total number of publications written about "Tegafur" by people in Harvard Catalyst Profiles by year, and whether "Tegafur" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 |
1997 | 0 | 1 | 1 |
1998 | 2 | 0 | 2 |
2001 | 0 | 2 | 2 |
2004 | 1 | 0 | 1 |
2005 | 0 | 1 | 1 |
2006 | 2 | 0 | 2 |
2008 | 1 | 0 | 1 |
2009 | 1 | 1 | 2 |
2011 | 1 | 0 | 1 |
2012 | 1 | 2 | 3 |
2013 | 0 | 2 | 2 |
2014 | 0 | 1 | 1 |
2015 | 1 | 5 | 6 |
2016 | 2 | 3 | 5 |
2017 | 1 | 2 | 3 |
2018 | 2 | 2 | 4 |
2019 | 0 | 3 | 3 |
2020 | 0 | 1 | 1 |
2021 | 1 | 0 | 1 |
Below are the most recent publications written about "Tegafur" by people in Profiles.
-
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model. Nagoya J Med Sci. 2021 Nov; 83(4):683-696.
-
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer. Br J Cancer. 2021 10; 125(9):1217-1225.
-
Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems. Sci Rep. 2020 10 26; 10(1):18278.
-
Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged =75?years) with non-small cell lung cancer: A retrospective analysis. Thorac Cancer. 2020 10; 11(10):2867-2876.
-
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. BMC Cancer. 2019 Apr 29; 19(1):397.
-
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019 05 20; 37(15):1296-1304.
-
[A Case of Gastric Small Cell Carcinoma with Rapid Regrowth after Surgery]. Gan To Kagaku Ryoho. 2019 Jan; 46(1):145-147.
-
[A Case of Type 4 Gastric Cancer with Esophageal Invasion That Responded to Neoadjuvant Chemotherapy Containing S-1 and Oxaliplatin followed by Surgery]. Gan To Kagaku Ryoho. 2018 Dec; 45(13):2327-2329.
-
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer. 2019 01; 106:78-88.
-
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Invest New Drugs. 2019 04; 37(2):338-344.